Many H3R ligands have demonstrated attractive benefits in various preclinical models for neuropsychiatric and neurodegenerative diseases, including cognitive deficits [5,6], attention deficit hyperactivity disorder [7,8,9], autistic behavior [10,11,12], epilepsy [13,14], and depression [15,16,17]. This evidence concerns the gene HRH3 and depressive symptom measurement.